Physician profile
Rena Ahuja
NPI 1710054127
$1,629.38
in general payments reported to CMS, 2019-2025
13 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $16.21 · 2022: $388 · 2023: $441 · 2024: $206 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $403.22 | 2022-2025 | Wegovy, Saxenda |
| Ibsa Pharma INC. | $268.91 | 2022-2023 | Tirosint, Licart |
| Amgen INC. | $227.42 | 2022-2023 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $179.84 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $157.06 | 2020-2025 | Airsupra |
| Vifor Pharma, INC. | $113.08 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.57 | 2022 | |
| Inari Medical, INC. | $55.03 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.35 | 2023-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $39.27 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $32.67 | 2023 | |
| Novartis Pharmaceuticals Corporation | $27.21 | 2025 | |
| Idorsia Pharmaceuticals US INC | $20.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Ahuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.